F O U R T H   Q U A R T E R   2 0 1 4
holiday banner

From the Director


Welcome to Tufts CSDD's fourth Quarterly Update of 2014, presenting an overview of current CSDD research, recent publications, staff presentations, and other news.


It's been a busy and exciting quarter, punctuated with the release on November 18th, at a media event held at Tufts School of Medicine, of our newest estimate of the cost of drug development. After making some brief opening remarks, I introduced the study's lead author, Dr. Joseph DiMasi, who went through the methodology and the results of his analysis for the media folks in attendance, as well as for the many participants who called in to the simultaneous webcast. The new estimate of $2.56 billion - fully capitalized and including the cost of failures - represents a 145% increase in constant dollars over our previous estimate published in 2003. Not surprisingly, our new study has generated considerable discussion, and continues to be covered by news sources around the world. I'm extremely proud that CSDD is the sole source of this profoundly important series, and that our estimates are relied on and used by developers, regulators, investors, and policy-makers worldwide.


CSDD Director Ken Kaitin with Dr. Yonghao Gui (left), Dean of Shanghai Medical College of Fudan University, and Dr. Liming Shao (right), Professor and Director of Fudan's Shanghai Center for Drug Discovery and Development 


In other news, I had the honor in early November to visit Fudan University in Shanghai, China, where I received an academic appointment as Consulting Professor. I also gave lectures to students in the College of Medicine and the School of Pharmacy. But the main purpose of my trip was to kick-off a new collaboration between Tufts CSDD and Fudan's newly created Shanghai Center for Drug Discovery and Development, run by Professor and Director Liming Shao. The goals of the collaboration are to conduct joint research on development trends in China and the U.S., to offer a drug development training program in China similar to CSDD's annual Postgraduate Course, to co-sponsor symposia, and to have an intern exchange program. For our first joint activity, Dr. Shao and I will be co-chairing a panel on biotech development at the 17th Shanghai International Forum on Biotechnology and the Pharmaceutical Industry in June 2015. I'm extremely excited about this new collaboration, and I look forward to sharing our activities with you in future Quarterly Updates.


It's been a productive and fulfilling year for us here at the Tufts Center, and I'm looking forward to an equally successful 2015. On behalf of the entire CSDD staff, I wish you and yours a happy, healthy, and peaceful holidays season. And as always, I thank you for your support. 




Kenneth I Kaitin, Ph.D.
Professor and Director

Research Opportunities 

As part of its broad research agenda, CSDD runs Multi-Company Working Groups and conducts Sponsored Research on a wide variety of topics identified by individual or multiple sponsors. Here is a list of projects currently in progress:

Multi-Company Working Group Studies

  • Evaluating the Impact of Integrated Outsourcing Relationships on Performance and Quality
  • Measuring the Adoption of eClinical Solutions and Standards
  • Social Media in Clinical Research Standard Practices and Policies 

Sponsored Research

  • Challenges Facing Biosimilar Uptake
  • Current Landscape for Personalized Medicines
  • Impact of Reimbursement on Innovation
  • Mapping Product-Specific Adverse Event Reporting in Institutional and Ambulatory Settings  
  • Pandemic & Bioterror Medical Countermeasures (MCMs)
  • Personalized Medicine Landscape
  • Public/Private Sector Contributions to R&D
Email us if you are interested in participating in one of our Multi-Company Working Groups, or if you would like additional information about sponsoring research at CSDD.
Recent CSDD Publications   


Getz KA, Lamberti MJ, Kaitin KI. Taking the pulse of strategic outsourcing relationships. Clinical Therapeutics. 2014;36(10):1349-1355.


Kaitin KI. Integrated partnerships and the transformation of pharmaceutical research and development. Clinical Therapeutics. 2014;36(10):1346-1348.


Stergiopoulos S, Getz KA. Social listening to enhance clinical research. Global Forum. 2014;6(5):17-20.

Latest Tufts CSDD Reports


Tufts CSDD Impact Report: 

Tufts CSDD R&D Management Report:

Upcoming Staff Presentations 
Selected presentations given or scheduled to be given by Tufts CSDD staff:



Mary Jo Lamberti: Partnerships in Clinical Trials, Barcelona, Spain, November 4-6


Mary Jo Lamberti: CDISC International Interchange, Bethesda, MD, November 12


Joseph DiMasi: R&D Cost Study Forum, Boston, MA, November 18


Joseph DiMasi: Drug Development Boot Camp, Boston, MA, November 19-20


Joshua Cohen: Tufts Global Health Research and Innovation Day, Boston, MA, November 20


Christopher Milne: Novartis Symposium, Bogota, Columbia, November 21



Joshua Cohen: IBC Vaccine Development & Production Summit, Boston, MA, December 8


Kenneth Getz: Princess Margaret Cancer Centre, Toronto, Canada, December 12


Joshua Cohen: Northeastern Global Health Lectures, Boston, MA, December 19



Kenneth Getz: Clinical Development Summit, Austin, TX, January 12-13, 2015


Kenneth Kaitin: MassBio Policy Leadership Breakfast (panel), Boston, MA, January 28, 2015.



Mary Jo Lamberti: SCOPE (Summit for Clinical Operations Executives), Orlando, FL, February 24-26, 2015

I N   T H I S   I S S U E
FYI. . .
On November 18th, Tufts CSDD released its newest estimate of the cost of drug development. Go to CSDD's website to see copies of the cost study press release, a methodology background, and the press briefing slide deck.
. . . . . . . . . 

Registration for Tufts CSDD's 42nd Annual Postgraduate Course in Clinical Pharmacology, Drug Development, and Regulation (February 2-6, 2015) is underway. Enrollment is limited, so register today.
. . . . . . . . .  
Find Tufts CSDD on Twitter, LinkedIn and Facebook!
Stay informed about upcoming events and courses, promotional specials on our various publications, the latest press releases and more! Follow us today:


Follow us on TwitterView our profile on LinkedInLike us on Facebook
 Tufts CSDD in the News

Over the past quarter, CSDD faculty have been featured and their research cited in over 50 news sources. Of note, CSDD's release of its newest estimate of the cost of drug development received very broad coverage, both nationally (e.g., the Wall Street Journal, the New York Times, the Chicago Tribune, Forbes, Reuters, and the Boston Globe) and internationally (e.g., the Times of India, the New Zealand Herald, MSN Argentina, and the Eurasia Review).

 Quote of the Quarter
"R&D costs are an important component of the profitability of new drug development, and are important in assessing incentives for innovation. So if R&D costs are increasing over time but reimbursement levels in general are remaining the same, you'd expect less drug development."
-Joseph DiMasi, Tufts CSDD

The Pink Sheet Daily
November 18, 2014


Kenneth I Kaitin, PhD 
Professor and Director

Christopher-Paul Milne, DVM, MPH, JD
Director of Research and Research Associate Professor

Joseph A. DiMasi, PhD
Director of Economic Analysis and ResearchAssociate Professor 

Joshua P. Cohen, PhD
Associate Professor

Kenneth A. Getz, MBA
Director of CSDD Sponsored Research Program and Research Associate Professor

Ronald Evens, PharmD, FCCP
Adjunct Research Professor


Richard I. Shader, MD
Medical Consultant and Professor Emeritus, Molecular Physiology and Pharmacology

Mary Jo Lamberti, PhD
Senior Research Fellow
Stella Stergiopoulos, BA
Senior Project Manager
Ranjana Chakravarthy, BA
Research Analyst

Pili Kamenju, MPH

Research Analyst


Sandra Peters, MLIS
Information Services Librarian
Tufts CSDD
617.636.2170 | csdd.tufts.edu